Ikonisys SA (ALIKO) - Cash Flow Conversion Efficiency

Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. It offers Ikoniscope Robotic Microscopes, including Ikoniscope20 that provides automated slide handling, slide scanning, and real-time image capture and analysis; and Ikoniscope20max that automates the fluorescence microscopy solution. The company also provides oncoFISH bladder that allows scanning and analysis of cells from a voided urine sample; oncoFISH her2, a microscopy application for the determination of the HER2 status of tissue sections from breast tissue biopsies; oncoFISH anaplastic lymphoma kinase (ALK), a microscopy application for the FISH based detection of gene rearrangements commonly associated with non-small cell lung carcinoma; oncoFISH PTEN, a microscopy application for the FISH based detection of deletions of the PTEN gene, which is prostate tissue biopsies; circulating tumor cells for characterization of individual tumor cells and ctDNA for global tumor genotype information; Ikonisoft explorer, a FISH scanning application for analysis of cell suspension deposited on a slide that has been hybridized with desired combination of FISH probes; and IkoniWAN Gateway, a validated remote access solution for Ikoniscope digital microscopy systems. In addition, it offers liquid biopsy/CTC bladder cancer detection and breast cancer early diagnostics products; CYTOfast vial solution for any type of cellular analysis; CYTOfast kit urine, a three day cytological urine test solution; CYTOfast PLUS, a liquid-phase processor that prepares thin-layer cytological samples from liquid-phase specimen; and Ikonisys intelligent application, a software designed to automatically quantify, qualify, and present cells for review. Ikonisys S.A. was incorporated in 2021 and is headquartered in Paris, France.